

GUIDE FOR THE USE OF ANTIPSYCHOTICS IN OLDER PEOPLE

REFERENCES

- i. Laver K, et al. Clinical practice guidelines for dementia in Australia. MJA 204 (5) j 21 March 2016
- ii. NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People 2016. Clinical Practice Guidelines and Principles of Care for People with Dementia available at: <https://www.clinicalguidelines.gov.au/portal/2503/clinical-practice-guidelines-and-principles-care-people-dementia> accessed 22nd May 2016
- iii. Greenblatt HK, Greenblatt DJ. Use of antipsychotics for the treatment of behavioural symptoms of dementia. J Clin Pharmacol 2016. Doi: 10.1002/jcph.731.
- iv. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596-608.
- v. Schneider L, Tariot P, Dagerman K, Davis S, Hsiao J, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-38.
- vi. Seitz et al. Pharmacological treatments for neuropsychiatric symptoms of dementia in long term care: a systematic review. Int Psychogeriatr 2013; 25(2): 185-203.
- vii. The Royal Australian and New Zealand College of Psychiatrists. The use of antipsychotics in residential aged care. 2011. http://www.bpac.org.nz/a4d/resources/docs/RANZCP_Clinical_recommendations.pdf.
- viii. Fraser L, Lui K, Naylor KL et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med 2015; 175(3): 450-452.
- ix. Helen C. Kales. Et al. Risk of Mortality Among Individual Antipsychotics in Patients with Dementia. Am J Psychiatry. 2012 January ; 169(1): 71-79. doi:10.1176/appi.ajp.2011.11030347
- x. Maust DT, Kim HM, Seyfried LS, Chiang C, et al. Antipsychotics, other psychotropics and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015; 72(5): 438-445.
- xi. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134.
- xii. Woeltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170:1395.
- xiii. Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol 2007; 27:595.
- xiv. Mittal V, Kurup L, Williamson D, Muralee S, Tampi R. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: A literature review of the evidence. Am J Alz Dis and Oth Dementias 2011; 26 (1) 10-28.
- xv. Simoni-Wastila L et al. Mortality risk of antipsychotic dose and duration in nursing home residents with chronic or acute indications. J Am Geriatr Assoc 2016 doi; 10.1111/jgs.14111
- xvi. <https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-6-number-4-august-2015> accessed 16th May 2016
- xvii. NPS Medicinewise. Antipsychotic Review Checklist. Available at agedcare.nps.org.au/__data/.../NPS-Aged-Care-Antipsychotic-Review-Checklist.pdf accessed 22nd May 2016